Form 4: Celldex Therapeutics Executive Exercises Stock Options
Statement of Changes in Beneficial Ownership
Ronald Pepin, Celldex Therapeutics' SR. VP & CBO, exercised stock options for 19,333 shares of common stock on December 15, 2025.
Summary
- Ronald Pepin, SR. VP & CBO of Celldex Therapeutics, Inc. (CLDX), reported transactions on December 15, 2025.
- Pepin exercised an incentive stock option to acquire 8,333 shares of common stock at an exercise price of $9.0165 per share.
- Pepin also exercised another incentive stock option to acquire 11,000 shares of common stock at an exercise price of $2.78 per share.
- Following these transactions, Pepin beneficially owns a total of 20,097 shares of common stock, which includes 764 shares acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
- The first option (8,333 shares) was fully vested as of June 13, 2022, and the second option (11,000 shares) was fully vested as of June 19, 2023.
- A 1-for-15 reverse stock split was effected on February 8, 2019, which adjusted the terms of the first option.
Sentiment
Score: 6
Explanation: The exercise of stock options by a senior executive is generally a neutral to slightly positive signal, indicating the executive is taking ownership of shares, which can imply confidence in the company's long-term prospects. It is a routine compensation event.
Positives
- An executive exercising options can signal confidence in the company's future prospects, as they are choosing to convert their options into shares.
- The options were exercised at prices significantly below the implied current market price, representing a gain for the executive.
Negatives
- The exercise of options can lead to a slight increase in the number of outstanding shares, resulting in minor dilution for existing shareholders.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This Form 4 filing reports a routine insider transaction (option exercise) and does not provide information directly related to broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: Minor potential dilution due to the issuance of new shares upon option exercise, but generally a routine event related to executive compensation.
Key Dates
| Date | Description |
|---|---|
| 02/08/2019 | Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock. |
| 06/13/2022 | First incentive stock option (8,333 shares) became fully vested. |
| 06/19/2023 | Second incentive stock option (11,000 shares) became fully vested. |
| 12/15/2025 | Date of stock option exercises by Ronald Pepin. |
| 12/17/2025 | Date the Form 4 was signed and filed. |
Keywords
Celldex Therapeutics, CLDX, Form 4, Insider Transaction, Stock Options, Executive Compensation, Ronald Pepin, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.